Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.

Oncogene - 1 Jan 2019

Kim In-Kyu, McCutcheon Justine N, Rao Guanhua, Liu Stephen V, Pommier Yves, Skrzypski Marcin, Zhang Yu-Wen, Giaccone Giuseppe

Abstract excerpt

Resistance to chemotherapy remains a critical barrier to effective cancer treatment. Although cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small cell lung cancer (NSCLC), mechanisms of resistance to this drug are not fully understood. Here, we report a novel cisplatin-resistance mechanism involving SET Domain Containing 2 (SETD2), a histone H3 lysine 36 (H3K36)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Cyclic AMP Response Element-Binding Protein

Share to Drug Resistance, Neoplasm

Share to Histone-Lysine N-Methyltransferase

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 30093630
DOI: 10.1038/s41388-018-0429-3
PMCID: PMC8274951

Genes

SETD2
SET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.PMID 30093630Read ↗

SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent mannerSemantic proximity Read ↗

[Research progress on the expression and carcinogenic mechanisms of SETD2 in malignant tumors].Semantic proximity Read ↗

Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1‐ABCG2 signalingSemantic proximity Read ↗

Downregulation of CISD2 Has Prognostic Value in Non-Small Cell Lung Cancer and Inhibits the Tumorigenesis by Inducing Mitochondrial DysfunctionSemantic proximity Read ↗

SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.Semantic proximity Read ↗

Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

A Novel Role for the Tumor Suppressor Gene ITF2 in Lung Tumorigenesis and Chemotherapy ResponseSemantic proximity Read ↗

Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the ThyroidSemantic proximity Read ↗

A novel role for the tumor suppressor gene <i>ITF2</i> in lung tumorigenesis and chemotherapy responseSemantic proximity Read ↗

Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.Semantic proximity Read ↗

Increased ABCC2 expression predicts cisplatin resistance in non‐small cell lung cancerSemantic proximity Read ↗

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.